Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ping Chi

Showing results (231-240 of 264) with videos related to

Pageof 27
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 2, 2017
Patient perspectives on ipilimumab across the melanoma treatment trajectoryElyse Shuk, Alexander N Shoushtari, Jason Luke, et al.
The Oncologist|October 10, 2015
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue SarcomasRodrigo R Munhoz, Sandra P D'Angelo, Mrinal M Gounder, et al.
Biorxiv : the Preprint Server for Biology|June 19, 2024
TAD hierarchy restricts poised LTR activation and loss of TAD hierarchy promotes LTR co-option in cancerElissa W P Wong, Merve Sahin, Rui Yang, et al.
The Journal of Surgical Research|April 6, 2013
Liver transplantation in acute-on-chronic liver failure patients with high model for end-stage liver disease (MELD) scores: a single center experience of 100 consecutive casesBin-Wei Duan, Shi-Chun Lu, Meng-Long Wang, et al.
JAMA Oncology|January 24, 2020
Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical TrialCiara M Kelly, Cristina R Antonescu, Timothy Bowler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2023
A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced SarcomaCiara M Kelly, Li-Xuan Qin, Karissa A Whiting, et al.
Journal for Immunotherapy of Cancer|May 4, 2026
Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcomaEvan Rosenbaum, Kenneth Seier, Rodrigo Gularte-Mérida, et al.
European Journal of Cancer (Oxford, England : 1990)|August 20, 2023
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label studyHans Gelderblom, Robin L Jones, Jean-Yves Blay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2024
Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with SarcomaSujana Movva, Kenneth Seier, Viswatej Avutu, et al.
The Journal of Clinical Investigation|July 19, 2022
Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic virusesJuan Yan, Yuedan Chen, Amish J Patel, et al.
Pageof 27

Showing results (231-240 of 264) with videos related to

Sort By:
Pageof 27
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 2, 2017
Patient perspectives on ipilimumab across the melanoma treatment trajectoryElyse Shuk, Alexander N Shoushtari, Jason Luke, et al.
The Oncologist|October 10, 2015
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue SarcomasRodrigo R Munhoz, Sandra P D'Angelo, Mrinal M Gounder, et al.
Biorxiv : the Preprint Server for Biology|June 19, 2024
TAD hierarchy restricts poised LTR activation and loss of TAD hierarchy promotes LTR co-option in cancerElissa W P Wong, Merve Sahin, Rui Yang, et al.
The Journal of Surgical Research|April 6, 2013
Liver transplantation in acute-on-chronic liver failure patients with high model for end-stage liver disease (MELD) scores: a single center experience of 100 consecutive casesBin-Wei Duan, Shi-Chun Lu, Meng-Long Wang, et al.
JAMA Oncology|January 24, 2020
Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical TrialCiara M Kelly, Cristina R Antonescu, Timothy Bowler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2023
A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced SarcomaCiara M Kelly, Li-Xuan Qin, Karissa A Whiting, et al.
Journal for Immunotherapy of Cancer|May 4, 2026
Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcomaEvan Rosenbaum, Kenneth Seier, Rodrigo Gularte-Mérida, et al.
European Journal of Cancer (Oxford, England : 1990)|August 20, 2023
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label studyHans Gelderblom, Robin L Jones, Jean-Yves Blay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2024
Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with SarcomaSujana Movva, Kenneth Seier, Viswatej Avutu, et al.
The Journal of Clinical Investigation|July 19, 2022
Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic virusesJuan Yan, Yuedan Chen, Amish J Patel, et al.
Pageof 27